Search Results - "TURCICH, Michelle"

Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer by INNOCENTI, Federico, SCHILSKY, Richard L, KARRISON, Theodore, MAITLAND, Michael L, SALGIA, Ravi, RATAIN, Mark J, RAMIREZ, Jacqueline, JANISCH, Linda, UNDEVIA, Samir, HOUSE, Larry K, DAS, Soma, KEHUA WU, TURCICH, Michelle, MARSH, Robert

“…The risk of severe neutropenia from treatment with irinotecan is related in part to UGT1A1*28, a variant that reduces the elimination of SN-38, the active…”
Get full text

Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib by Ramírez, Jacqueline, House, Larry K., Karrison, Theodore G., Janisch, Linda A., Turcich, Michelle, Salgia, Ravi, Ratain, Mark J., Sharma, Manish R.

“…This study investigated the time course and magnitude of the pharmacokinetic interaction between capecitabine and the cytochrome P450 (CYP) 2C9 substrate…”
Get full text

A drug-drug interaction study of capecitabine and celecoxib in patients with advanced solid malignancies by Ramirez, Jacqueline, House, Larry, Karrison, Theodore G., Janisch, Linda A., Turcich, Michelle, Salgia, Ravi, Ratain, Mark J., Sharma, Manish

“…Abstract only e14066 Background: Warfarin is an anticoagulant and CYP2C9 substrate commonly used in oncology patients. Several studies suggest a drug-drug…”
Get full text

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors by Sehdev, Amikar, Karrison, Theodore, Zha, Yuanyuan, Janisch, Linda, Turcich, Michelle, Cohen, Ezra E. W., Maitland, Michael, Polite, Blase N., Gajewski, Thomas F., Salgia, Ravi, Pinto, Navin, Bissonnette, Marc B., Fleming, Gini F., Ratain, Mark J., Sharma, Manish R.

“…Background Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor. Metformin may potentiate mTOR inhibition by sirolimus while mitigating its adverse…”
Get full text

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors by Sehdev, Amikar, Zha, Yuanyuan, Karrison, Theodore G., Janisch, Linda A., Cohen, Ezra E.W., Maitland, Michael L., Polite, Blase N., Turcich, Michelle, Fleming, Gini F., Salgia, Ravi, Pinto, Navin R., Gajewski, Thomas, Bissonnette, Marc, Ratain, Mark J., Sharma, Manish

“…Abstract only TPS11628 Background: Sirolimus is an inhibitor of the mammalian target of rapamycin (mTOR). Metformin has shown anti-cancer activity through its…”
Get full text

Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients by SHARMA, Manish R, KARRISON, Theodore G, SCHILSKY, Richard L, RATAIN, Mark J, COHEN, Ezra E. W, KELL, Bethany, KEHUA WU, TURCICH, Michelle, GEARY, David, KANG, Soonmo P, TAKEBE, Naoko, GRAHAM, Richard A, MAITLAND, Michael L

“…Vismodegib, an orally bioavailable small-molecule Smoothened inhibitor, is approved for treatment of advanced basal cell carcinoma (BCC). We conducted a…”
Get full text

A genotype-directed study to optimize dosing of irinotecan according to the UGT1A1 genotype by Innocenti, Federico, Salgia, Ravi, Ramirez, Jacqueline, Janisch, Linda A., Undevia, Samir D., House, Larry, Das, Soma, Wu, Kehua, Turcich, Michelle, Marsh, Robert de Wilton, Karrison, Theodore, Maitland, Michael L., Schilsky, Richard L., Ratain, Mark J.

“…Abstract only 2570 Background: The risk of severe neutropenia from irinotecan (I) is in part related to UGT1A1*28, a polymorphism that reduces the elimination…”
Get full text

Evaluation of food effect on pharmacokinetics (PK) of GDC-0449 (G) in advanced solid tumor patients by Sharma, Manish, Kang, Soonmo Peter, Karrison, Theodore, Wu, Kehua, Turcich, Michelle, Geary, David, Takebe, Naoko, Graham, Richard A., Maitland, Michael L., Schilsky, Richard L., Ratain, Mark J., Cohen, Ezra E. W.

“…Abstract only e13106 Background: GDC-0449 (Vismodegib, Genentech), an orally bioavailable small-molecule SMO (Smoothened) inhibitor, was recently approved for…”
Get full text